A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

By S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, Frederick L. Baehner, Michael G. Walker, D. Watson, T. Park and 8 more. New England Journal of Medicine, 2004

5,932 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/07eec256ef567a114f80822f224d6e045f7fbab3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Genetics

In Pathology and Forensic Medicine

Citations in the corpus

Latent Variable Models (2019, methodology): “Several studies demonstrated that tumor grade was a strong prognostic factor (Laroye & Minkin, 1991; Paik et al., 2004; Theissig et al., 1990).”
Machine learning applications in cancer prognosis and prediction (2014, methodology): “In the DREAM project [68], several attempts to combine clinical treatment scores with signatures based on immunohistochemistry [69] as well as expression-based signatures such as PAM50 [70] and Oncotype DX [71] reveal the extensive work done for improving treatment based on the incorporation of diff”
Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling (2011, methodology): “Many of these signatures have also been shown to be prognostic factors and identify patients at increased risk of developing distant metastases [45, 46], including a 70gene prognosis signature [1, 44], a 76 gene prognosis signature [47] and a 21-gene classifier for paraffin-embedded tissues (Oncotyp”
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. (2006, methodology): “developed and validated a 21-gene assay that is now offered as a commercial reference laboratory test (Oncotype DX, Genomic Health Inc, Redwood City, CA).(14,15) The 21-gene panel includes genes involved in tumor cell proliferation and hormonal response, characteristics that have been reported to be”
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies (2008, methodology): “Another genomic microarray, Oncotype DX ® (Genomic Health, Redwood City, CA), based on quantitative real-time PCR, has been commercially available for the same use since 2004 since the validation of its gene signature for predicting the recurrence of tamoxifen-treated, node-negative breast cancer”
GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, positive): “In addition, CCNB1 is also included in several prognostic gene signatures such as the 21-gene recurrence score [10] and two genomic grade signatures [35,36].”
From cancer patient to cancer survivor : lost in transition (2006, background): “…become part of the standard initial evaluation of patients, treatment of late effects may decline as therapies are tailored to individual risk (Paik et al., 2004; Mrozek and Shapiro, 2005). aNuclear grade is an evaluation of the size and shape of the nucleus in tumor cells and the percentage…”
SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis (2013, methodology): “As an example for testing one biomarker in several datasets, we used the 16 OncotypeDX genes [14].”
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, methodology): “After the prognostic algorithm was developed in these test data sets, Oncotype DX was validated by the analysis of specimens and data from a second set of patients with node-negative, ER-positive breast cancer treated only with tamoxifen, who were enrolled in the NSABP clinical trial B-14.”